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The aim of the study is to examine the risk of sickness absence in public sector employees with
allergic rhinitis or asthma or both conditions combined.
This is a prospective cohort study of 48 296 Finnish public sector employees. Data from self-
reported rhinitis and asthma were obtained from survey responses given during either the
2000e2002 or 2004 periods. Follow-up data on sickness absences for the public sector
employees surveyed were acquired from records kept by the employers.
During the follow-up, mean sick leave days per year for respondents were 17.6 days for
rhinitis alone, 23.8 days for asthma alone and 24.2 days for both conditions combined. Respon-
dents with neither condition were absent for a mean of 14.5 days annually. The impact of
asthma and rhinitis combined on the risk of sick leave days was marginal compared to asthma
alone (RR 1.1; 95% CI 1.0e1.3). In the subgroup analysis (those with current asthma or allergy
medication), the risk ratio for medically certified sickness absence (>3 days) was 2.0 (95% CI
1.9e2.2) for those with asthma and rhinitis combined.
Rhinitis, asthma and both these conditions combined increased the risk of days off work.
ª 2010 Elsevier Ltd. All rights reserved.471 86523; fax: þ358 9 471
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Nasal symptoms and signs caused by allergen exposure and
IgE-mediated inflammation are called allergic rhinitis.1
Medications such as acetosalicylic acid, occupational
exposures, foods including spices, physical and chemical.
Allergic rhinitis is associated with an increased risk of sickness absences 1655factors in addition to prolonged viral infections may cause
similar symptoms and signs.
In Finland, the prevalence of allergic rhinitis has been
reported to vary between 7% and 9%2e4 whereas the prev-
alence of asthma varies between 3% and 11%.2e4 In a recent
8-year follow-up study both allergic rhinitis (OR 3.5; 95% CI
2.1e5.9) and non-allergic rhinitis (OR 2.7; 95% CI 1.6e4.5)
increased asthma risk significantly.5 The prevalence of
rhinitis as a comorbidity with asthma has been estimated to
be 50% in patients with non-allergic asthma in USA and
Europe and up to 100% in patients with allergic asthma.6
The use of health care systems including physician and
emergency room visits, the occurrence of asthma attacks
and the taking of medication have all been higher for
asthma patients who also have rhinitis as a comorbidity
compared with asthma patients without rhinitis.6,7 It has
been estimated that every fourth patient with allergic
rhinitis will have taken one day off work within any one
year.8 These authors also reported that most of the
productivity loss resulted from reduced at-work produc-
tivity associated with the use of sedating antihistamines
and not from work absenteeism per se. In the United
States, allergic rhinitis is estimated to result in 3.5 million
lost work-days and 2 million lost school-days annually.9
In this large occupational cohort study, we examined the
risk of absenteeism due to illness (sick leave) associated
with allergic rhinitis with or without asthma in Finland.Material and methods
This study is part of the Finnish Public Sector Study of local
government employees in 10 towns and 21 public hospitals
in Finland.10,11 We included full-time employees who
responded to a survey conducted either in 2000e2002
(NZ 48 598) or in 2004 (NZ 48 076), a combined sample of
66 418 employees (74% of the eligible employees responded
at least once, the first response only was considered for
those responding twice). The baseline survey was per-
formed in 8 towns and in 4 hospital districts in 2000 and in
additional 2 towns in 2001 and in additional 2 hospital
districts in 2001e2002. The follow-up survey was performed
in 2004. We excluded 6358 individuals who were employed
for less than six months during the follow-up, which began
after the survey. Of the remaining 60 060 employees, 51 616
individuals gave their consent for a linkage to be made
between employees’ sick leave records maintained by the
employers and the survey responses. The final sample
consisted of 48 296 participants who responded to questions
about asthma and rhinitis. The mean age of the individuals
was 45.0 years (range from 19 to 66 years; SD 9.4) and 80%
were females. The study was approved by the Ethics
Committee of the Finnish Institute of Occupational Health.
Respondents were coded as positive for asthma or
allergic rhinitis based on the survey responses regarding
physician-diagnosed asthma or allergic rhinitis including
seasonal rhinitis. Each individual was categorized as having
rhinitis alone, asthma alone, both asthma and rhinitis
combined or neither. In addition, we analyzed subgroups
for each patient category including those participants only
who, during the survey year, had purchases of asthma
medication (asthma alone, asthma and rhinitis) or allergymedication (rhinitis alone, asthma and rhinitis). Informa-
tion on medication purchases according to World Health
Organizations’ Anatomical Therapeutic Chemical (ATC)
classification code were obtained from the Drug Prescrip-
tion Register of the Social Insurance Institution of Finland.
Asthma medication included drugs for obstructive airway
diseases (ATC code R03). Allergy medication included nasal
corticosteroids (R01AD), antihistamines for systemic use
(R06), and nasal anti-allergic agents excluding corticoste-
roids (R01AC).
Data on sickness absences from January 1 following the
survey year until December 31, 2005 were analyzed for: the
number of self-certified sickness absence periods (3
days), the number of medically certified sickness absence
periods (>3 days), and the total number of sickness
absence days per person-year.
Information on age, sex, and socioeconomic status (SES)
of the employees were also obtained from the employer-
maintained records. SES was categorized according to the
occupational-title classification of ‘Statistics Finland’ for:
upper-grade non-manual workers, lower-grade non-manual
workers, and manual workers such as cleaners and main-
tenance workers. Information regarding smoking and body
mass index (BMI, kg/m2) at the beginning of the follow-up
was taken from the survey responses. Respondents repor-
ted if they had never smoked, or were ex-smokers, or were
current smokers. Employees BMIs were dichotomized to
indicate obesity category (>30) or non-obesity (30).
The Chi-square test was used to analyze differences in
frequency distribution of categorical baseline data in the
four classified conditions (rhinitis alone, asthma alone,
rhinitis and asthma combined, and neither). Age was
treated as continuous variable and analysis of variance was
used. Poisson regression models were used to calculate the
rate of self-certified and medically certified sick leaves per
person-year in addition to the corresponding rate ratios
(RR) and their 95% confidence intervals (CI) for each
respondent. Regression models based on negative binomial
distributions were used for analyzing the number of sick-
ness absence days.10,11 The rate ratios were adjusted for
sex, age, socioeconomic status, smoking, and obesity. All
analyses were performed using the SAS statistical software,
version 9.1.3 (SAS Institute, Inc., Cary, North Carolina).Results
The median follow-up period was 4 (interquartile range
1e5) years. A life-time diagnosis of self-reported allergic
rhinitis was reported by 24.2% of the respondents, 1.8% had
asthma only, 4.7% had both conditions. In contrast, 69.2%
had neither of the conditions. Rhinitis and asthma were
more common among women, non-manual workers,
ex-smokers, and obese individuals (Table 1). Study
respondents with asthma only were older than those with
rhinitis only or rhinitis and asthma in combination.
During the follow-up, the respondents with rhinitis took
a mean of 17.6 sickness absence days per year (RR 1.3; 95%
CI 1.2e1.3); those with asthma 23.8 days (RR 1.5; 95% CI
1.4e1.7); and those with both conditions combined 24.2
days (RR 1.7; 95% CI 1.6e1.8). This compared to a mean of
only 14.5 days for subjects without either diagnosis
Table 1 Baseline characteristics
Rhinitis
(NZ 11 695)
Asthma
(NZ 883)
Asthma and rhinitis
(NZ 2276)
Reference
(NZ 33 442)
N % N % N % N %
Age (mean, SD) 42.8 9.4 47.3 9.2 43.9 9.7 45.4 9.3
Female gender 9502 81.2 709 80.3 1918 84.3 26 535 79.3
Current smokers 1961 17.2 174 20.4 365 16.5 5987 18.4
BMI more than 30 1243 10.8 163 18.8 347 15.5 3664 11.1
Sickness absence
(number/1 py)
Self-certified spells
(1e3 days)
1.61 1.59 1.84 1.27
Medically certified
spells (>3 days)
0.86 1.14 1.16 0.67
Absence days 17.55 23.78 24.19 14.46
SDZ standard deviation; BMIZ body mass index, pyZ person-year.
1656 P. Kauppi et al.(Tables 1 and 2). Further adjustments for smoking and
obesity did not alter the results. Asthma and rhinitis
together increased the risk more (RR 1.7; 95% CI 1.6e1.8)
than for asthma alone (Table 2).
The rate ratios for the number of self-certified sickness
absence periods (3 days) after adjusting for age, sex, and
SES were 1.2 (95% CI 1.2e1.2) in subjects with rhinitisTable 2 Risk of sickness absence and number of lost work-days
Condition Self-certified sickness
absence (1e3days)
RR (95% CI)
Model 1
Reference (NZ 33 442) 1.00 (ref.)
Rhinitis (NZ 11 695) 1.21 (1.18e1.23)
Asthma (NZ 883) 1.27 (1.20e1.35)
Asthma and rhinitis (NZ 2 276) 1.38 (1.33e1.43)
Model 2
Reference 1.00 (ref.)
Rhinitis 1.20 (1.18e1.22)
Asthma 1.26 (1.19e1.34)
Asthma and rhinitis 1.38 (1.33e1.42)
Cases with current medication
Model 1
Reference (NZ 33 442) 1.00 (ref.)
Rhinitis (NZ 3041) 1.26 (1.22e1.30)
Asthma (NZ 445) 1.29 (1.19e1.40)
Asthma and rhinitis (NZ 675) 1.54 (1.45e1.63)
Model 2
Reference 1.00 (ref.)
Rhinitis 1.26 (1.22e1.30)
Asthma 1.28 (1.17e1.38)
Asthma and rhinitis 1.56 (1.47e1.65)
Model 1 was controlled for age, gender and socioeconomic status and
subgroup analyses included those participants only who, during the s
alone, asthma and rhinitis) or allergy medication (groups: rhinitis aloalone, 1.3 (95% CI 1.2e1.4) in those with asthma alone and
1.4 (95% CI 1.3e1.4) in those having both conditions
compared to those with neither condition. Rate ratios were
slightly higher for medically certified absences than for
self-certified absences. Respondents with rhinitis alone had
1.3 times greater a risk of medically certified sickness
absences (95% CI 1.3e1.4), whereas those with asthmaMedically certified
sickness absence (>3 days)
Number of sickness
absence days
RR (95% CI) RR (95% CI)
1.00 (ref.) 1.00 (ref.)
1.32 (1.29e1.35) 1.27 (1.23e1.30)
1.63 (1.53e1.73) 1.52 (1.39e1.67)
1.75 (1.69e1.82) 1.73 (1.64e1.84)
1.00 (ref.) 1.00 (ref.)
1.32 (1.29e1.35) 1.25 (1.22e1.29)
1.60 (1.51e1.70) 1.46 (1.33e1.60)
1.73 (1.67e1.80) 1.73 (1.63e1.83)
1.00 (ref.) 1.00 (ref.)
1.40 (1.35e1.45) 1.31 (1.25e1.38)
1.75 (1.62e1.90) 1.63 (1.43e1.86)
2.02 (1.90e2.15) 1.93 (1.74e2.15)
1.00 (ref.) 1.00 (ref.)
1.42 (1.36e1.47) 1.32 (1.25e1.39)
1.73 (1.59e1.87) 1.58 (1.38e1.80)
2.03 (1.91e2.16) 1.96 (1.76e2.18)
Model 2 was additionally controlled for smoking and obesity. The
urvey year, had purchases of asthma medication (groups: asthma
ne, asthma and rhinitis).
Allergic rhinitis is associated with an increased risk of sickness absences 1657alone had a 1.6 times greater risk (95% CI 1.5e1.7), and
those with both conditions 1.8 times greater risk (95% CI
1.7e1.8). The subgroup analyses replicated and strength-
ened the results (Table 2).
Risk of self-certified sickness absences was 1.1 times
greater (95% CI 1.0e1.2) in the asthma and rhinitis
combined group compared to those with asthma alone after
adjusting for age, sex, and SES. Similarly, risk of medically
certified sickness absences was 1.1 times greater (95% CI
1.0e1.2) and of increased number of lost work-days were
1.1 times greater (95% CI 1.0e1.3) in the asthma and
rhinitis combined group compared to those with asthma
alone (P< 0.03). No change in the rate ratios was observed
after adjustments for smoking and obesity. In the subgroup
analyses after full adjustments, RR for self-certified sick-
ness absences was 1.2 (95% CI 1.1e1.3), for medically
certified sickness absences 1.2 (95% CI 1.1e1.3), and for
number of lost work-days 1.2 (95% CI 1.1e1.5).Discussion
To our knowledge this is the first prospective longitudinal
study reporting sickness absences in public sector
employees with allergic rhinitis, asthma or both. This study
found an increased risk of sickness absences for those
employees who reported physician-diagnosed self-reported
allergic rhinitis, asthma or both of these conditions
combined. The results were replicated and strengthened in
participants with registered use of asthma or allergy
medication during the survey year. The total number of sick
leave days taken was significantly higher in both the asthma
alone group and the asthma and rhinitis combined group. At
6.5%, the prevalence of asthma as diagnosed by a physician
in the self-reported asthma group was similar to those
reported in other Finnish studies.2e4 However, the preva-
lence of self-reported life-time allergic rhinitis diagnosed
by a physician in our study was 24%, which was somewhat
higher than those reported in the earlier studies.2e4
The strengths of this study are its large study population
and the prospective follow-up of all sickness absences from
employers’ records. In addition, the response rate at 74%
was high making the study sample representative of Finnish
public sector employees.
In this study, employees with rhinitis had a mean of 3.1
sickness absence days per person-year more than the
reference group without rhinitis or asthma. This is a greater
excess risk than reported in a previous study, where every
fourth patient with allergic rhinitis was estimated to have
taken one day off work within any one year.8 The produc-
tivity loss associated with allergic rhinitis has been sug-
gested to result from reduced performance due to use of
sedating antihistamines rather than from work absen-
teeism.9 We found estimation of productivity loss vulner-
able to many biases and did not include any analysis on at-
work productivity. In Sweden, which is comparable to
Finland in many geographical and socioeconomic aspects,
severe nasal symptoms associated with allergic rhinitis
were found to be related to lower school grade sum.12
In our study population, prevalence of self-reported
asthma diagnosed by a physician was 6.5%. This is in
agreement with a Norwegian study reporting theprevalence of asthma complaints to be 5% in year 2003. In
that study, allergic complaints decreased by 12% from year
1996 to 2003 but prevalence of sickness absences caused by
allergy increased only by 5% in the same time interval.13
Asthma as a subjective health complaint increased by 66%
but sickness absences caused by asthma decreased by 7%
from year 1996 to 2003. In our study, future surveys will
allow analysis of trends in sickness absences associated
with rhinitis and asthma.
The actual causes for sick leaves taken were not
analyzed in this study since the specific causes for the sick
leaves cannot be tracked down in this database. Viral
respiratory infections are known to trigger wheezing and
asthma exacerbations. Such viral infections are suggested
to at least partly play role in the development of allergies
and asthma.14e16 Thus one of the most likely explanations
for the increased number of sickness absences found in this
study is the exacerbation of allergic rhinitis and asthma
caused by viral infections.
In addition to actual cause for sick leaves, data on
rhinitis and asthma symptoms in previous 12 months would
give more information of the likelihood of rhinitis and
asthma as the cause for absenteeism. However, in these
surveys these diseases have been processed as physician-
diagnosed allergic rhinitis or asthma. Furthermore, self-
reported physician-diagnosed disease is widely used in
epidemiological studies and considered as accurate indi-
cator whereas symptoms of rhinitis only are often rather
unspecific. Also, the subgroup analyses in those with
registered use of asthma or allergy medication during the
survey year strengthened the results. This is in line with the
study by Alexopoulos and Burdorf, where asthmatic
complaints in the past 12 months were associated with
increased sickness absences during the study follow-up.17
The limitations of the study include lack of information
on asthma or rhinitis symptoms, asthma or rhinitis severity
and the specific causes for the sickness absences. Infor-
mation on symptoms and severity of disease as well as
diagnose for sickness absences would allow more accurate
analysis on the causes of absences. In addition, our study
population is mostly women (79e84%) and one has to be
cautious when generalizing the results into men. In a recent
review of studies of employees with a chronic somatic
disease, work disability in asthma was weakly associated
with asthma severity score and female gender and moder-
ately associated with occupation (blue-collar work).18
Unfortunately, we had no opportunity to analyze asthma
severity and sickness absences but we included both gender
and socioeconomic status in adjusted multivariate models
and found asthma and rhinitis to be independent risk
factors for sickness absences.
These results indicate that both allergic rhinitis and
asthma add to the economic burden of sick leave absen-
teeism affecting the employee, his or her employer and to
society as a whole. The lack of treatment of allergic
rhinitis, its under-treatment and also non-adherence to
treatment all increase the costs associated with allergic
rhinitis.19 Although this study does not demonstrate the
benefits of therapy for allergic rhinitis in terms of reduced
sick leave absences, our findings do emphasize the need for
self-guided management and sufficient treatment by health
practitioners in general.1,19
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